Drugs / ES16001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05525182 | Jul 2021 → Dec 2023 | COVID-19 | Genencell Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ES16001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05525182 ↗ |
| Route | Oral | “Elaeocarpus extract 40mg tablet” NCT05525182 ↗ |